V900268
Sodium phosphate dibasic dodecahydrate
Vetec™, reagent grade, 99%
Synonym(s):
sec-Sodium phosphate, Disodium hydrogen phosphate dodecahydrate, Disodium phosphate, di-Sodium hydrogen phosphate dodecahydrate
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Linear Formula:
Na2HPO4 · 12H2O
CAS Number:
Molecular Weight:
358.14
UNSPSC Code:
12352300
PubChem Substance ID:
EC Number:
231-448-7
MDL number:
Assay:
99%
Grade:
reagent grade
Form:
powder or crystals
grade
reagent grade
product line
Vetec™
assay
99%
form
powder or crystals
pH
8.4-9.6 (25 °C, 35.8 g/L)
SMILES string
O.O.O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O
InChI
1S/2Na.H3O4P.12H2O/c;;1-5(2,3)4;;;;;;;;;;;;/h;;(H3,1,2,3,4);12*1H2/q2*+1;;;;;;;;;;;;;/p-2
InChI key
DGLRDKLJZLEJCY-UHFFFAOYSA-L
Legal Information
Vetec is a trademark of Merck KGaA, Darmstadt, Germany
Still not finding the right product?
Explore all of our products under Sodium phosphate dibasic dodecahydrate
Storage Class
11 - Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Matthew R Weir et al.
Journal of clinical hypertension (Greenwich, Conn.), 16(12), 875-882 (2014-10-21)
The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure (BP) and osmotic diuresis- and intravascular volume reduction-related adverse events (AEs) were evaluated using pooled data from four placebo-controlled, phase 3 studies in patients with type 2
George G S Sandor et al.
International journal of cardiology, 179, 470-475 (2014-12-04)
Patients with Marfan (MFS) and Loeys-Dietz (LDS) syndromes have been shown to have abnormal aortic biophysical properties. The purpose of this study was to compare the effects of 12-months of therapy with atenolol or losartan on vascular function in young
Karen Sliwa et al.
Heart (British Cardiac Society), 100(24), 1967-1974 (2014-09-18)
Lack of evidence-based data on the spectrum of cardiovascular disease (CVD) in pregnancy or in the postpartum period, as well as on maternal and fetal outcome, provides challenges for treating physicians, particularly in areas of low resources. The objectives of
Global Trade Item Number
| SKU | GTIN |
|---|---|
| V900268-6X500G | 04061833645185 |
| V900268-500G | 04061833494813 |